secwatch / observer
8-K filed February 5, 2026, 6:59 PM ET CIK 0001839133
leadership confidence high sentiment negative materiality 0.60

IR-Med raises $43,619 from director-led private placement; CEO Ran Ziskind resigns

IR-Med, Inc.

item 1.01item 3.02item 5.02item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

IR-Med, Inc. entered into Securities Purchase Agreement with certain investors valued at aggregate gross proceeds of $43,619 (effective 2026-02-04).

Action
entry
Agreement
equity purchase
Counterparty
certain investors
Value
aggregate gross proceeds of $43,619
Effective
2026-02-04
Exact text from the filing
On February 4, 2026, IR-Med, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (each an “Investor” and, collectively, the “Investors”), pursuant to which the Company agreed to issue and sell, in a private placement offering (the “Offering”), an aggregate of 14,070,644 shares of the Company’s common stock, par value $0.001 per share, (the “Common Stock”), at a per share price of $0.0031 and a warrant to purchase up to an additional 7,035,322 shares of Common Stock (the “Warrants”) at a per share exercise price of $0.03 (the “Exercise Price”).
View on SEC.gov

329 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR
accession 0001493152-26-005258
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.